Sign in Subscribe
Cancer

Breakthrough in Cancer Gene Therapy: Baylor College of Medicine Presents HydrAd

Strategic Insights

— 1 min read

Researchers at Baylor College of Medicine in Houston, Texas, have made a significant breakthrough in cancer gene therapy with the development of HydrAd, a helper-dependent adenovirus that targets multiple immune pathways for cancer treatment. According to a new report, HydrAd has the potential to provide a promising cancer immunotherapy agent against complex solid tumors. The research, published in the journal Cancers, explores the mechanism of action of HydrAd, which expresses multiple classes of immunomodulatory molecules to stimulate immune pathways and induce tumor cell lysis.

Key Takeaways:

  • HydrAd is a helper-dependent adenovirus that has been designed to target multiple immune pathways for cancer treatment.
  • The virus has well-characterized genomes, allowing for substantial modifications, including capsid chimerism and therapeutic transgene insertion.
  • HydrAd has a transgene capacity of up to 34 kb, making it an ideal cancer gene therapy vector.
  • The virus's infection results in anti-viral immune stimulation that can be enhanced or redirected towards the tumor via transgene expression.
  • Co-infection of tumor cells with an oncolytic Ad and an HDAd results in tumor cell lysis and amplification of HDAd-encoded transgene expression.
  • The HydrAd platform represents a promising cancer immunotherapy agent against complex solid tumors.
  • The research was conducted by a team of researchers at Baylor College of Medicine, including Amanda Rosewell Shaw, Caroline Porter, Greyson Biegert, Lisa Jatta, and Masataka Suzuki.

Statistics:

  • The transgene capacity of HydrAd is up to 34 kb.
  • The virus's infection results in anti-viral immune stimulation.
  • Co-infection of tumor cells with an oncolytic Ad and an HDAd results in tumor cell lysis and amplification of HDAd-encoded transgene expression.
  • The research was published in the journal Cancers, which has a high impact factor and is a leading publication in the field of cancer research.

Sources:

  • HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers, 2022,14(2769):2769. (Cancers - http://www.mdpi.com/journal/cancers/)
  • NewsRx. New Cancer Gene Therapy Research from Baylor College of Medicine Outlined (HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy). Cancer Weekly. June 28, 2022; p 52.

Read more